News and Insights

Nov 10, 2026

Congratulations to Vittoria Biotherapeutics on receiving FDA RMAT and Orphan Drug designations for Senza5 CART5 (VIPER-101) for the treatment of T-cell lymphoma

Read

Oct 14, 2026

We’re excited to announce our investment in Altay Therapeutics and partner with its team to bring a new oral treatment to patients living with FSHD.

Read

Oct 5, 2026

Thrilled that our portfolio company, Alveus Therapeutics Inc., has been recognized as one of Fierce Biotech's Fierce 15

Read

Sep 14, 2026

Congratulations to our portfolio company Alveus Therapeutics on launching the Phase 2 PRESERVE trial, an important step toward helping patients sustain weight loss over the long term:

Read

Jun 3, 2026

ShiraTronics Completes Enrollment in RELIEV-CM2 Pivotal Trial of Implantable Extracranial Neuromodulation Systems (IENs) for Chronic Migraine

Read

May 7, 2026

Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline

Read

May 7, 2026

Odyssey CEO talks about $279M IPO and building a 'permanent' biotech

Read

Mar 3, 2026

ARTICLE | Emerging Company Profile
Alveus: Best-in-class opportunity in obesity

Read

Feb 24, 2026

Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

Read

Feb 24, 2026

Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer

Read

Jan 23, 2026

Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

Read

Jan 7, 2026

Acesion Pharma Initiates Phase 2 Clinical Trial of AP31969 for Treatment of Atrial Fibrillation

Read

Jan 6, 2026

Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation

Read

Jan 6, 2026

Cartography does another pharma deal, this time with Pfizer

Read

Oct 2, 2025

Proud to support Cartography Biosciences in developing precision immunotherapies for microsatellite-stable colorectal cancer.

Read

Sep 22, 2025

Thrilled that our portfolio company, Nuvig Therapeutics Inc., has been recognized as one of FierceBiotech's Fierce 15.

Read

Sep 16, 2025

ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine

Read

Sep 10, 2025

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to
Advance Clinical Pipeline for Autoimmune Diseases

Read

May 29, 2025

Vittoria Biotherapeutics to Present VIPER-101 Phase 1 Trial at 2025 ASCO Annual Meeting (MyChesCo)

Read

May 14, 2025

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data (Nuvig Therapeutics)

Read

Apr 23, 2025

Treating Autoimmune Diseases: Four New Technologies To Watch (Forbes)

Read

Apr 7, 2025

Who should we be watching on the USA biotech stage? (DDW-Online)

Read

Apr 7, 2025

Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company

Read

Mar 21, 2025

The most funded women-led life sciences companies in the Bay Area in 2024

Read

Dec 19, 2024

TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance First-in-Class Engineered IgA Monoclonal Antibody for Cancer and Infectious Diseases

Read

Dec 5, 2024

Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

Read

Nov 12, 2024

Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates

Read

Oct 9, 2024

ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine

Read

Sep 27, 2024

Odyssey Therapeutics Announces Formation of Scientific Advisory Board

Read

Sep 26, 2023

Acesion clinches $47M in Series B raise to advance preclinical cardiac arrhythmia candidate through PhII

Read

Sep 7, 2021

RMG-KB BIOACCESS FUND LAUNCHES with Worldwide Focus on Innovative Life Sciences Ventures

Read

News and Insights

Join our mailing list

Congratulations to Vittoria Biotherapeutics on receiving FDA RMAT and Orphan Drug designations for Senza5 CART5 (VIPER-101) for the treatment of T-cell lymphoma

We’re excited to announce our investment in Altay Therapeutics and partner with its team to bring a new oral treatment to patients living with FSHD.

Thrilled that our portfolio company, Alveus Therapeutics Inc., has been recognized as one of Fierce Biotech's Fierce 15

Congratulations to our portfolio company Alveus Therapeutics on launching the Phase 2 PRESERVE trial, an important step toward helping patients sustain weight loss over the long term:

ShiraTronics Completes Enrollment in RELIEV-CM2 Pivotal Trial of Implantable Extracranial Neuromodulation Systems (IENs) for Chronic Migraine

Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline

Odyssey CEO talks about $279M IPO and building a 'permanent' biotech

ARTICLE | Emerging Company ProfileAlveus: Best-in-class opportunity in obesity

Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer

Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

Acesion Pharma Initiates Phase 2 Clinical Trial of AP31969 for Treatment of Atrial Fibrillation

Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation

Cartography does another pharma deal, this time with Pfizer

Proud to support Cartography Biosciences in developing precision immunotherapies for microsatellite-stable colorectal cancer.

Thrilled that our portfolio company, Nuvig Therapeutics Inc., has been recognized as one of FierceBiotech's Fierce 15.

ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing toAdvance Clinical Pipeline for Autoimmune Diseases

Vittoria Biotherapeutics to Present VIPER-101 Phase 1 Trial at 2025 ASCO Annual Meeting (MyChesCo)

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data (Nuvig Therapeutics)

Treating Autoimmune Diseases: Four New Technologies To Watch (Forbes)

Who should we be watching on the USA biotech stage? (DDW-Online)

Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company

The most funded women-led life sciences companies in the Bay Area in 2024

TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance First-in-Class Engineered IgA Monoclonal Antibody for Cancer and Infectious Diseases

Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates

ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine

Odyssey Therapeutics Announces Formation of Scientific Advisory Board

Acesion clinches $47M in Series B raise to advance preclinical cardiac arrhythmia candidate through PhII

RMG-KB BIOACCESS FUND LAUNCHES with Worldwide Focus on Innovative Life Sciences Ventures

ARTICLE | Emerging Company Profile
Alveus: Best-in-class opportunity in obesity

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to
Advance Clinical Pipeline for Autoimmune Diseases